This solo survival trip lasted 30 days in constant rain, where staying dry became the hardest part of every day. Building ...
People who've had no one to lean on often keep others at arm's length, even people who genuinely want to be close. They may test relationships, expect disappointment, or pull away before they can be ...
Onvansertib combined with FOLFIRI and Avastin shows dose-dependent improvements in tumor response and disease control for RAS ...
Relay Therapeutics upgraded to Outperform: zovegalisib PI3Kα breast cancer catalyst, $596M cash to 2029, Phase 3 mid-2026.
The FDA has granted breakthrough therapy designation (BTD) for bezuclastinib in combination with sunitinib (Sutent) for the ...